These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 29311381)

  • 21. Recruiting T cells in cancer immunotherapy.
    Yost KE; Chang HY; Satpathy AT
    Science; 2021 Apr; 372(6538):130-131. PubMed ID: 33833111
    [No Abstract]   [Full Text] [Related]  

  • 22. Integrating T cell metabolism in cancer immunotherapy.
    Dugnani E; Pasquale V; Bordignon C; Canu A; Piemonti L; Monti P
    Cancer Lett; 2017 Dec; 411():12-18. PubMed ID: 28974448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD147‑mediated reprogrammed glycolytic metabolism potentially induces immune escape in the tumor microenvironment (Review).
    Li X; Xu W
    Oncol Rep; 2019 May; 41(5):2945-2956. PubMed ID: 30864716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. To Remember or to Forget: The Role of Good and Bad Memories in Adoptive T Cell Therapy for Tumors.
    Mondino A; Manzo T
    Front Immunol; 2020; 11():1915. PubMed ID: 32973794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory circuits of T cell function in cancer.
    Speiser DE; Ho PC; Verdeil G
    Nat Rev Immunol; 2016 Oct; 16(10):599-611. PubMed ID: 27526640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.
    Waibl Polania J; Lerner EC; Wilkinson DS; Hoyt-Miggelbrink A; Fecci PE
    Front Immunol; 2021; 12():777073. PubMed ID: 34868044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treg programming and therapeutic reprogramming in cancer.
    Moreno Ayala MA; Li Z; DuPage M
    Immunology; 2019 Jul; 157(3):198-209. PubMed ID: 30866047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complementing T-cell Function: An Inhibitory Role of the Complement System in T-cell-Mediated Antitumor Immunity.
    Peng W; McKenzie JA; Hwu P
    Cancer Discov; 2016 Sep; 6(9):953-5. PubMed ID: 27587467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
    Reiser J; Banerjee A
    J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment.
    Zhao Y; Shao Q; Peng G
    Cell Mol Immunol; 2020 Jan; 17(1):27-35. PubMed ID: 31853000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival of the fittest: Cancer challenges T cell metabolism.
    Franchina DG; He F; Brenner D
    Cancer Lett; 2018 Jan; 412():216-223. PubMed ID: 29074426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aging: T cell metabolism within tumors.
    Zhang Y; Ertl HC
    Aging (Albany NY); 2016 Jun; 8(6):1163-4. PubMed ID: 27282177
    [No Abstract]   [Full Text] [Related]  

  • 35. Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries.
    Ho PC; Kaech SM
    Curr Opin Immunol; 2017 Jun; 46():38-44. PubMed ID: 28458087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Collagen density regulates the activity of tumor-infiltrating T cells.
    Kuczek DE; Larsen AMH; Thorseth ML; Carretta M; Kalvisa A; Siersbæk MS; Simões AMC; Roslind A; Engelholm LH; Noessner E; Donia M; Svane IM; Straten PT; Grøntved L; Madsen DH
    J Immunother Cancer; 2019 Mar; 7(1):68. PubMed ID: 30867051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
    Houot R; Schultz LM; Marabelle A; Kohrt H
    Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
    Fares CM; Van Allen EM; Drake CG; Allison JP; Hu-Lieskovan S
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():147-164. PubMed ID: 31099674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy.
    Tang H; Qiu X; Timmerman C; Fu YX
    Methods Mol Biol; 2018; 1845():275-286. PubMed ID: 30141019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Obesity induced T cell dysfunction and implications for cancer immunotherapy.
    Aguilar EG; Murphy WJ
    Curr Opin Immunol; 2018 Apr; 51():181-186. PubMed ID: 29655021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.